Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

991 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study.
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Itani H, Endo T, Saito AM, Shibayama T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: kurata t. JTO Clin Res Rep. 2023 Apr 6;4(6):100514. doi: 10.1016/j.jtocrr.2023.100514. eCollection 2023 Jun. JTO Clin Res Rep. 2023. PMID: 37304652 Free PMC article.
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan.
Goto Y, Kenmotsu H, Tamiya M, Murakami S, Kurata T, Yanagitani N, Taniguchi H, Kuyama S, Shimizu J, Yokoyama T, Shimada N, Maeda T, Tamiya A, Uchiyama A, Imaizumi K, Takahama T, Kato T, Hayashi H, Shiraiwa N, Toyoizumi S, Kikkawa H, Thomaidou D, Nishio M. Goto Y, et al. Among authors: kurata t. JTO Clin Res Rep. 2023 Mar 24;4(5):100508. doi: 10.1016/j.jtocrr.2023.100508. eCollection 2023 May. JTO Clin Res Rep. 2023. PMID: 37250506 Free PMC article.
Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia.
Katsushima U, Fukushima T, Nakano J, Ogushi N, Fujii K, Nagata Y, Kamisako K, Okuno Y, Okazaki Y, Nakanishi K, Yoshida K, Ikoma T, Takeyasu Y, Yamanaka Y, Yoshioka H, Hase K, Kurata T. Katsushima U, et al. Among authors: kurata t. Thorac Cancer. 2024 Dec 9. doi: 10.1111/1759-7714.15503. Online ahead of print. Thorac Cancer. 2024. PMID: 39654007 Free article.
Author Correction: A virally encoded tRNA neutralizes the PARIS antiviral defence system.
Burman N, Belukhina S, Depardieu F, Wilkinson RA, Skutel M, Santiago-Frangos A, Graham AB, Livenskyi A, Chechenina A, Morozova N, Zahl T, Henriques WS, Buyukyoruk M, Rouillon C, Saudemont B, Shyrokova L, Kurata T, Hauryliuk V, Severinov K, Groseille J, Thierry A, Koszul R, Tesson F, Bernheim A, Bikard D, Wiedenheft B, Isaev A. Burman N, et al. Among authors: kurata t. Nature. 2024 Dec;636(8043):E8. doi: 10.1038/s41586-024-08427-4. Nature. 2024. PMID: 39633059 Free PMC article. No abstract available.
Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer.
Yamanaka Y, Ota T, Masuoka Y, Takeyasu Y, Nakamura S, Terashima M, Yoshioka H, Fukuoka M, Kurata T. Yamanaka Y, et al. Among authors: kurata t. Cancers (Basel). 2024 Sep 11;16(18):3127. doi: 10.3390/cancers16183127. Cancers (Basel). 2024. PMID: 39335099 Free PMC article.
991 results